This strategic relationship is expected to support company’s preparation for an investigational new drug application for Homspera.
Efforts to be pursued at Lovelace will involve both the inhalational administration of Homspera, which was used in early radioprotection studies, as well as the intranasal administration used more recently in the studies demonstrating anti-viral activity, vaccine adjuvant activity, and hematologic stem cell.